Literature DB >> 11884930

Inhibitory effects of immunosuppressive drugs on insulin secretion from HIT-T15 cells and Wistar rat islets.

B W Paty1, J S Harmon, C L Marsh, R P Robertson.   

Abstract

Until recently, islet allotransplantation for type 1 diabetic patients has been largely unsuccessful. Previous pharmacologic studies of single drugs have suggested that one factor contributing to this poor success is toxicity of immunosuppressive drugs on transplanted islets. However, no comprehensive study of agents currently used for islet transplantation has been previously reported. Consequently, we exposed HIT-T15 cells and Wistar rat islets to various concentrations of five immunosuppressive agents for 48 and 24 hr, respectively, and measured glucose-stimulated insulin secretion during subsequent static incubations. Results are expressed as percent reduction of insulin secretion at the lower and upper limits, respectively, of plasma drug concentrations used in clinical transplantation compared with control (no drug exposure). Insulin secretion from HIT-T15 cells was significantly inhibited by 74% and 90% after exposure to methylprednisolone (P<0.05), 11% and 24% after exposure to cyclosporine (P<0.01), 60% and 83% after exposure to mycophenolate (P<0.05), 56% and 63% after exposure to sirolimus (P<0.001), and 10% and 20% after exposure to tacrolimus (P<0.001). Insulin secretion from Wistar rat islets was reduced by 0% and 48% after exposure to mycophenolate (P<0.001) and 20% and 31% after exposure to tacrolimus (P<0.05). No reduction in insulin secretion was observed from either HIT-T15 cells or rat islets after exposure to daclizumab. The results support the hypothesis that toxicity of certain immunosuppressive drugs on beta-cell function plays a role in the poor success of islet allotransplantation. This is especially true of intrahepatically transplanted islets, which are exposed to higher portal concentrations of immunosuppressive agents. These findings support the use of low-dose immunosuppressive drug protocols in clinical islet transplantation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11884930     DOI: 10.1097/00007890-200202150-00007

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  27 in total

1.  alpha-lipoic acid regulates AMP-activated protein kinase and inhibits insulin secretion from beta cells.

Authors:  E D Targonsky; F Dai; V Koshkin; G T Karaman; A V Gyulkhandanyan; Y Zhang; C B Chan; M B Wheeler
Journal:  Diabetologia       Date:  2006-05-13       Impact factor: 10.122

Review 2.  Cellular therapies for type 1 diabetes.

Authors:  D D Lee; E Grossman; A S Chong
Journal:  Horm Metab Res       Date:  2008-02       Impact factor: 2.936

Review 3.  Current challenges in islet transplantation.

Authors:  Cristiane B Leitão; Pablo Cure; Thipaporn Tharavanij; David A Baidal; Rodolfo Alejandro
Journal:  Curr Diab Rep       Date:  2008-08       Impact factor: 4.810

4.  The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells.

Authors:  C T Bussiere; J R T Lakey; A M J Shapiro; G S Korbutt
Journal:  Diabetologia       Date:  2006-08-09       Impact factor: 10.122

Review 5.  Encapsulated cell grafts to treat cellular deficiencies and dysfunction.

Authors:  N V Krishnamurthy; Barjor Gimi
Journal:  Crit Rev Biomed Eng       Date:  2011

6.  Extracellular factors and immunosuppressive drugs influencing insulin secretion of murine islets.

Authors:  V J Auer; E Janas; V Ninichuk; E Eppler; T S Weiss; S Kirchner; A M Otto; M J Stangl
Journal:  Clin Exp Immunol       Date:  2012-11       Impact factor: 4.330

Review 7.  Clinical islet transplantation.

Authors:  Dixon B Kaufman; William L Lowe
Journal:  Curr Diab Rep       Date:  2003-08       Impact factor: 4.810

Review 8.  Islet transplantation a decade later and strategies for filling a half-full glass.

Authors:  R Paul Robertson
Journal:  Diabetes       Date:  2010-06       Impact factor: 9.461

9.  {beta}-Cell secretory capacity and demand in recipients of islet, pancreas, and kidney transplants.

Authors:  Michael R Rickels; Rebecca Mueller; Karen L Teff; Ali Naji
Journal:  J Clin Endocrinol Metab       Date:  2010-01-22       Impact factor: 5.958

10.  Rapamycin inhibits growth factor-induced cell cycle regulation in pancreatic beta cells.

Authors:  Amy Aronovitz; Jami Josefson; Amanda Fisher; Marsha Newman; Elizabeth Hughes; Fei Chen; David S Moons; Hiroaki Kiyokawa; William L Lowe
Journal:  J Investig Med       Date:  2008-12       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.